Breaking News Instant updates and real-time market news.

CCL

Carnival

$68.74

0.32 (0.47%)

, CUK

Carnival plc

$69.12

0.06 (0.09%)

08:58
09/15/17
09/15
08:58
09/15/17
08:58

Carnival downgraded to Neutral on capacity concerns at Credit Suisse

As previously reported, Credit Suisse analyst Tim Ramskill downgraded Carnival (CCL) to Neutral from Outperform, as he is worried that his estimate of absolute industry capacity growth in 2018-2021 is double that of the last five years. This capacity growth is a greater concern given demand risks, said Ramskill, who cited risk to the top 3 cruise markets - the Caribbean post Hurricane Irma, the Mediterranean post the Barcelona terror attacks and China with the Korea travel ban still in place. He cut his 2018 yield growth view to 1.5% from 3%, lowered his EPS estimate by 10% and dropped his price target on Carnival shares to $70 from $78. Other publicly traded cruise operators include Royal Caribbean (RCL) and Norwegian Cruise Line (NCLH).

CCL

Carnival

$68.74

0.32 (0.47%)

CUK

Carnival plc

$69.12

0.06 (0.09%)

RCL

Royal Caribbean

$123.55

1.36 (1.11%)

NCLH

Norwegian Cruise Line

$57.72

-0.07 (-0.12%)

  • 02

    Oct

CCL Carnival
$68.74

0.32 (0.47%)

08/02/17
GSCO
08/02/17
UPGRADE
Target $115
GSCO
Neutral
Royal Caribbean upgraded to Neutral from Sell at Goldman Sachs
Goldman Sachs analyst Stephen Grambling upgraded Royal Caribbean (RCL) to Neutral citing "strong" leisure trends following the company's better than expected Q2 results. The analyst says his sell thesis has failed to materialize. He raised his price target for the shares to $115 from $99. Grambling also raised his price target for Neutral-rated Carnival (CCL) to $68 from $60 and for Neutral-rated Norwegian Cruise Line (NCLH) to $60 from $55.
08/04/17
STFL
08/04/17
NO CHANGE
STFL
Norwegian Cruise Line should deliver beat and raise results, says Stifel
Stifel analyst Steven Wieczynski says that the results and comments of Royal Caribbean (RCL) and Carnival (CCL) indicate that Norwegian Cruise Line (NCL) will report beat and raise Q2 results. The analyst expects Norwegian, like Royal Caribbean and Carnival, to benefit from higher prices. He also expects Norwegian to be boosted by a reduction of "operational headwinds" which should enable its yield to rise more than that of its peers in 2018. The analyst keeps a $60 price target and a Buy rating on Norwegian.
08/17/17
UBSW
08/17/17
NO CHANGE
Target $76
UBSW
Buy
Carnival price target raised to $76 from $67 at UBS
UBS analyst Robin Farley raised her price target on Carnival to $76 from $67. The analyst noted guidance for the second half of the year is only up 1-2% but he believes the company is being conservative given tougher comps and the uncertainty around any travel incidents when looking out six months. Farley reiterated her Buy rating on Carnival shares.
09/15/17
FBCO
09/15/17
DOWNGRADE
Target $70
FBCO
Neutral
Carnival downgraded to Neutral from Outperform at Credit Suisse
Credit Suisse analyst Tim Ramskill downgraded Carnival to Neutral and cut his price target for the shares to $70 from $78.
CUK Carnival plc
$69.12

0.06 (0.09%)

09/29/16
09/29/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Owens Corning (OC) initiated with a Market Perform at Wells Fargo. 2. Kate Spade (KATE) was initiated with an Outperform at CLSA, while the firm initiated Coach (COH) with a Buy and Michael Kors (KORS) with a Sell. 3. RetailMeNot (SALE) and Groupon (GRPN) initiated with a Neutral at Boenning & Scattergood. 4. Carnival (CCL) initiated with a Hold at Deutsche Bank. 5. D.R. Horton (DHI) initiated with an Outperform at Wells Fargo. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/06/17
BERN
01/06/17
NO CHANGE
Target $63
BERN
Outperform
Carnival OCEAN platform to be 'powerful competitive advantage,' says Bernstein
Bernstein analyst David Beckel said Carnival's OCEAN "connected experience" platform, unveiled at CES 2017, could, and likely will, be emulated to some extent across the entire travel industry. However, citing Carnival's head start, scale, and technology expertise, he sees OCEAN becoming a "powerful competitive advantage for the company for years to come." Beckel keeps his Outperform rating and $63 price target on Carnival shares.
RCL Royal Caribbean
$123.55

1.36 (1.11%)

07/25/17
STFL
07/25/17
NO CHANGE
STFL
Royal Caribbean should be bought on any 'irrational' weakness, says Stifel
Stifel analyst Steven M. Wieczynski does not expect Royal Caribbean's Q2 results to significantly beat expectations, and he thinks investors' expectations for the results may be "unrealistic," particularly regarding the anticipation of increases in the company's 2017 guidance. However, he recommends buying the stock on any "irrational" weakness following the results, as he thinks that the company's 2018 results could beat his expectations and expects the company's multiple and capital returns to increase. He keeps a $125 price target and a Buy rating on the stock.
08/02/17
08/02/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Pfizer (PFE) upgraded to Outperform from Market Perform at BMO Capital with analyst Alex Arfaei saying he expects "positive updates" on the company's pipeline that could improve investors' view on the company. 2. Royal Caribbean (RCL) upgraded to Neutral from Sell at Goldman Sachs with analyst Stephen Grambling citing "strong" leisure trends following the company's better than expected second quarter results. 3. Illumina (ILMN) upgraded to Equal-Weight from Underweight at First Analysis with analyst Joseph Munda saying concerns regarding sequencing overcapacity in the marketplace and the potential rate of adoption for NovaSeq are diminishing based on performance in the quarter. 4. Agios Pharmaceuticals (AGIO) upgraded to Outperform from Market Perform at Leerink with analyst Michael Schmidt citing his higher-level conviction regarding the commercial opportunity for its IDH inhibitors Idhifa and ivosidenib in acute myeloid leukemia following Idhifa FDA-approval and his recent checks indicating a high degree of enthusiasm for these agents in the physician community pointing to potential good initial uptake. 5. Sonoco Products (SON) upgraded to Hold from Sell at Vertical Research with analyst Chip Dillion citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
NCLH Norwegian Cruise Line
$57.72

-0.07 (-0.12%)

05/26/17
WEDB
05/26/17
UPGRADE
WEDB
Outperform
Norwegian Cruise Line upgraded to Outperform from Neutral at Wedbush
07/24/17
BOFA
07/24/17
INITIATION
Target $65
BOFA
Buy
Norwegian Cruise Line initiated with a Buy at BofA/Merrill
BofA/Merrill analyst Andrew Didora initiated Norwegian Cruise Line with a Buy and a $65 price target saying shares trade at a discount to peers despite solid net yield trends, a newer fleet, and high margins.

TODAY'S FREE FLY STORIES

BBBY

Bed Bath & Beyond

$27.03

-0.27 (-0.99%)

05:12
09/20/17
09/20
05:12
09/20/17
05:12
Recommendations
Bed Bath & Beyond analyst commentary  »

Bed Bath & Beyond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLRN

Acceleron

$38.97

-0.41 (-1.04%)

05:10
09/20/17
09/20
05:10
09/20/17
05:10
Recommendations
Acceleron analyst commentary  »

Acceleron price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

ICPT

Intercept

$96.20

0.45 (0.47%)

05:01
09/20/17
09/20
05:01
09/20/17
05:01
Recommendations
Intercept analyst commentary  »

Intercept recent pullback…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YAHOY

Yahoo Japan

$9.02

-0.03 (-0.33%)

04:57
09/20/17
09/20
04:57
09/20/17
04:57
Downgrade
Yahoo Japan rating change  »

Yahoo Japan downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPZM

Epizyme

$19.25

1.4 (7.84%)

04:56
09/20/17
09/20
04:56
09/20/17
04:56
Initiation
Epizyme initiated  »

Epizyme initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 27

    Sep

CSGP

CoStar Group

$280.60

3.97 (1.44%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
CoStar Group management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

YEXT

Yext

$12.99

-0.27 (-2.04%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Yext management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

FCFS

First Cash Financial

$60.65

0.65 (1.08%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
First Cash Financial management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

  • 22

    Sep

VNRX

VolitionRx

$2.75

0.07 (2.61%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
VolitionRx management to meet with Oppenheimer »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

  • 25

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 28

    Sep

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Citigroup to hold a conference »

2017 SMID and Travel…

SRCL

Stericycle

$70.19

-0.81 (-1.14%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Stericycle management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

  • 27

    Sep

FIVN

Five9

$22.17

0.31 (1.42%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Five9 management to meet with Roth Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 25

    Sep

GMS

GMS Inc.

$33.50

-0.38 (-1.12%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
GMS Inc. management to meet with Seaport Global »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

HRTG

Heritage Insurance

$11.83

-0.72 (-5.74%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Heritage Insurance management to meet with Sandler O'Neill »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

HZNP

Horizon Pharma

$12.10

0.26 (2.20%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Horizon Pharma management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

OHI

Omega Healthcare

$32.53

-0.12 (-0.37%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Omega Healthcare management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

MZDAF

Mazda

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Mazda management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

SFS

Smart & Final Stores

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Smart & Final Stores management to meet with Loop Capital »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

SRCI

SRC Energy

$8.18

0.16 (2.00%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
SRC Energy management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 25

    Sep

  • 16

    May

EMR

Emerson

$63.21

0.22 (0.35%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Emerson management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

04:55
09/20/17
09/20
04:55
09/20/17
04:55
General news
Existing Home Sales to be reported at 10:00 »

August Existing Home…

SCSC

Scansource

$40.70

-0.05 (-0.12%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Scansource management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

ARLP

Alliance Resource Partners

$18.90

-0.05 (-0.26%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Alliance Resource Partners management to meet with MKM Partners »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Piper Jaffray to hold a tour »

Permian Basin BBQ &…

AITB

AIT Therapeutics

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
AIT Therapeutics management to meet with Roth Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 26

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.